The publication of this infographic was funded by Pierre Fabre Laboratories. It is intended for nurses in countries where neratinib (NERLYNX) is marketed.
Neratinib (NERLYNX®) is indicated for the extended adjuvant treatment of adult patients with early-stage HR+/HER2-overexpressed/amplified breast cancer, who completed adjuvant trastuzumab-based therapy <1 year ago. This infographic offers valuable guidance to nurses in effectively managing neratinib patients to ensure they reap the maximum advantages from this therapy.
